ImmunityBio
Founded Year
2014Stage
PIPE | IPOTotal Raised
$301.59MAbout ImmunityBio
ImmunityBio (NASDAQ: IBRX) is an immunotherapy company with a broad portfolio of biological molecules spanning albumin-linked chemotherapeutic, peptide, fusion protein, cytokine, monoclonal antibody, adenovirus, and yeast vaccine therapies. This platform of technologies has enabled ImmunityBio to achieve late-stage clinical pipelines addressing both the innate (activated macrophage and natural killer cell) and the adaptive immune system (dendritic, CD4, and CD8 killer T cells). The company was founded in 2014 and is based in Culver City, California.
Loading...
Loading...
ImmunityBio Patents
ImmunityBio has filed 50 patents.
The 3 most popular patent topics include:
- immune system
- immunology
- clusters of differentiation
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/11/2019 | 11/14/2023 | Clusters of differentiation, Immune system, Immunology, Transcription factors, Cell biology | Grant |
Application Date | 3/11/2019 |
|---|---|
Grant Date | 11/14/2023 |
Title | |
Related Topics | Clusters of differentiation, Immune system, Immunology, Transcription factors, Cell biology |
Status | Grant |
Latest ImmunityBio News
Nov 16, 2023
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 35th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 28-30, 2023. Details of the presentation can be found below. Piper Sandler Healthcare Conference Date Thursday, November 30, 2023 Time: 10:30 am EST Format: Fireside chat with Director and Senior Research Analyst Jo
ImmunityBio Frequently Asked Questions (FAQ)
When was ImmunityBio founded?
ImmunityBio was founded in 2014.
Where is ImmunityBio's headquarters?
ImmunityBio's headquarters is located at 9920 Jefferson Boulevard, Culver City.
What is ImmunityBio's latest funding round?
ImmunityBio's latest funding round is PIPE.
How much did ImmunityBio raise?
ImmunityBio raised a total of $301.59M.
Who are the investors of ImmunityBio?
Investors of ImmunityBio include NantCapital, NantKwest and Celgene.
Who are ImmunityBio's competitors?
Competitors of ImmunityBio include Prokarium.
Loading...
Compare ImmunityBio to Competitors
Prokarium is a biopharmaceutical company that focuses on developing vaccination and cancer immunotherapy solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company was founded in 2012 and is based in London, U.K.
Loading...